Tenaya Therapeutics, Inc.

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

Novartis AG has reached an agreement for exclusive global (excluding South Korea) development and commercialization rights to Chong Kun Dang Pharmaceutical Corp. 's (CKD) CKD-510, a selective, non-h

The pace of IPOs in 2022 is far below the record-breaking number of first-time offerings in 2021, with the last initial public offering in the US by a biopharmaceutical company completed by Acrivon T

Ten biopharmaceutical companies launched initial public offerings in the US during the last week of July, raising $1.2bn combined, bringing last month’s total to 18 IPOs. Added to the 62 first-time of